Business
PDS expands CRADA with National Cancer Institute
PDS expands CRADA with National Cancer Institute.
About this update from Emv Capital Plc
[{"type":"text","content":"\n \n \n RNS Number : 5136L\n NetScientific PLC\n 30 April 2020\n \n \n \n \n \n NetScientific plc\n (\"NetScientific\" or the \"Company\")\n \n PDS Biotechnology Expands CRADA with the National Cancer Institute to Include Second Versamune®-Based Anti-Cancer Product\n \n \n \n London, UK - 30 April 2020 - \n \n NetScientific plc (AIM: NSCI), the transatlantic healthcare IP commercialisation Group, today announces that its portfolio company PDS Biotechnology Corporation (\"PDS\") (Nasdaq: PDSB) announced yesterday (29 April 2020) an expansion of its previously announced Cooperative Research and Development Agreement (CRADA) with the National Cancer Institute (NCI) to include studies of PDS0103, a Versamune®-based product incorporating novel mucin-1 (MUC1) epitopes developed by the NCI. This expansion adds to the NCI's ongoing evaluation of PDS0101 in combination with two separate immune-modulating agents, NHS-IL12 and M7824, which will be evaluated in a phase 2 clinical trial in advanced HPV-associated cancers (NCT04287868).\n \n \n \n \n \n Below is the full announcement made yesterday (29 April 2020) by PDS Biotechnology.\n \n \n # # #\n \n \n PDS Biotechnology Expands CRADA with the National Cancer Institute to Include Second Versamune®-Based Anti-Cancer Product\n \n \n \n \n \n NCI to study PDS0103, in addition to planned Phase 2 clinical evaluation of PDS0101 in combination with other therapeutic agents\n \n \n \n \n \n Princeton, NJ, April 29, 2020 - PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing novel cancer therapies and infectious disease vaccines based on the Company's proprietary Versamune® T-cell activating technology, today announced an expansion of its previously announced Cooperative Research and Development Agreement (CRADA) with the National Cancer Institute (NCI) to include studies of PDS0103, a Versamune®-based product incorporating novel mucin-1 (MUC1) epitopes developed by the NCI. This expansion adds to the NCI's ongoing evaluation of PDS0101 in combination with two separate immune-modulating agents, NHS-IL12 and M7824, which will be evaluated in a phase 2 clinical trial in advanced HPV-associated cancers (NCT04287868).\n \n \n \n \n \n Under the expanded CRADA, PDS Biotech will coll...